Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.

Osteoporos Int · 2017 · PMC5306167 · PMID 28028555

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = .08so close (0.05 < p ≤ 0.1)

In Yu and colleagues’ study, hip fracture incidence appeared to decrease with longer exposure, though in multivariate models the association of teriparatide exposure and incidence did not reach statistical significance (persistence 1–6 vs 19–24 months: OR = 1.93; P = .08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.